Berberine8998 is a newly synthesized berberine derivative with better lipid-lowering activity and improved absorption. The objective of this study was to investigate the effects of berberine8998 on serum cholesterol and lipid levels in vivo and to examine the mechanisms involved. Hamsters on high-fat diet (HFD) were administered berberine or berberine8998 (50 mg·kg -1 ·d -1
Introduction
Berberine is an isoquinoline alkaloid ( Figure 1A ) and the main active constituent of Coptis chinensis Franch [1] . Berberine-containing herbs are used in traditional Chinese medicine to treat various conditions and diseases, including diarrhoea, cancer, depression, hypertension, hypercholesterolemia, and diabetes mellitus [2] . Berberine also exhibits significant lipid-lowering activity. Treatment of hypercholesterolemic patients with orally administered berberine reduced serum levels of cholesterol and low-density lipoprotein (LDL) by 29% and 25%, respectively. Berberine treatment reduced serum total cholesterol (TC) by 40% and LDL by 42% in hyperlipidemic hamsters [3] . However, the effect of berberine on triglycerides (TGs) and its associated mechanisms are not fully understood, but serum TG concentrations and risk for coronary heart disease are issues of great interest as well [4] . Fatty acids (FAs) are important metabolic substrates for energy production. Excess FAs triacylglycerol (TG) [5] . High serum LDL is a major risk factor for atherosclerosis and coronary heart disease [6, 7] , and is the main target of lipid-lowering drugs [8] . Berberine increases the abundance of LDL receptor (LDLR) [3] in the liver via transcript stabilization [9] . Upregulation of LDLR expression on the hepatocyte surface by genetic or pharmacological means has been shown to increase hepatic clearance and reduce serum levels of LDL cholesterol [10] [11] [12] . LDLR activity is therefore considered a key factor in determining LDL cholesterol concentrations in the systemic circulation.
Berberine and its derivatives reduce lipid levels via multiple mechanisms. Berberine reduces serum LDL-c via the induction of LDLR expression in the liver. Signaling pathway studies show that berberine activates AMPK, ERK and other pathliver [13] . The isobaric Tags for Relative and Absolute Quantitation powerful methodologies in quantitative proteomics, which has been used and reviewed in a variety of reports [14, 15] . Proteomics has a great potential in mechanism identification. Moreover, proteomics analysis permits effective expression measurements in large sample sets. Therefore, we used proteomics to analyze the mechanisms of the lipid-lowering effect of berberine.
One obstacle for berberine use in the treatment of hypercholesterolemia is its low bioavailability. An oral dose of its clinical application [16] derivatives with improved bioavailability will facilitate therapeutic applications.
In this study, a newly synthesized berberine derivative, berberine8998 ( Figure 1B ) was characterized. In vivo studies and TG levels in the hamster model, while berberine only lowered TC and TG levels. In-depth iTRAQ proteomics revealed that peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) and long-chain-fatty acid-CoA ligase 1 (ACSL1), proteins involved in fatty acid metabolism, were expressed differently in the berberine8998 group compared to the control and the berberine treatment groups. Mechanistic studies showed that berberine8998 significantly lowered non-esterified fatty acid (NEFA) levels, which may lead to a reduction in TG levels in berberine8998 treatment groups. Pharmacokinetic analyses showed that berberine8998 had remarkably improved absorption (by 7.74 times) compared to berberine. These findings suggest that berberine8998 lowered cholesterol and lipid levels via different mechanisms compared to berberine, and it is a promising therapeutic candidate for the treatment of hypercholesterolemia and obesity.
Materials and methods

Chemicals and reagents
Berberine (purity >98%) was purchased from Northeast Pharm (China). Berberine8998 (purity >97%) was synthesized by You-hong HU (Shanghai Institute of Materia Medica, Shanghai, China). Dulbecco's modified Eagle's medium (DMEM) was purchased from HyClone Laboratories (Logan, UT, USA). Fetal bovine serum (FBS) was obtained from ThermoFisher Scientific (Carlsbad, CA, USA). Provastatin was purchased from Sigma-Aldrich (St Louis, MO, USA).
Animals and procedures
Six-week-old hamsters were obtained from the Animal Center of Shanghai Institute of Materia Medica. Hamsters were randomly divided into four groups: normal diet, model, berberine, and berberine8998 groups. Berberine and berberine8998 were dissolved in CMC-Na prior to administration. Hamsters on the normal diet received carboxymethylcellulose sodium (CMCNa) as the negative control group (n=3). Hamsters on a high-fat diet (HFD) (0.15% cholesterol and 18% fat) were administered n=12) daily intragastrically for 3 weeks. Body weight was monitored. All hamsters were fasted overnight (12 h) at 7, 14 and 21 days post-dosing, and blood samples were drawn from the retro-orbital plexus into tubes containing 3.8% sodium citrate (w v) as an anti-coagulant. Blood samples (0.3-0.5 mL) were collected weekly after a 12 h fast and centrifuged for 15 min at 3000 ×g LDL-c and TG levels, were measured using an automatic analyzer (Hitachi, Tokyo, Japan).
Animal experiments were performed according to the National Research Council's Guidelines, and the Institutional Ethical Committee of Shanghai Institute of Materia Medica approved all experimental protocols and procedures.
Protein extraction and iTRAQ reagent labeling
To determine the protein expression differences between the berberine and berberine8998 treatment groups, livers of hamsters from the different treatment groups were collected, snapfrozen in liquid nitrogen, and stored at -80 °C. The samples at 70 W for 5 s at 10 s intervals, and homogenized three times using a whirlpool mixer at 10 min intervals. Samples were centrifuged at 20 000×g for 30 min at 4 °C, and the protein concentration in the supernatant was determined using a Bradford assay. BSA was used to generate the calibration curve.
Trypsin digestion and iTRAQ labeling were performed. -lated and digested overnight at 37 °C with trypsin (MS grade; Promega, Fitchburg, WI, USA). Samples were labeled with iTRAQ reagent (Applied Biosystems) as follows: berberine, used for the 12 digested protein samples.
Two-dimensional LC-MS/MS analysis based on Triple TOF 5600
Mixed peptides were fractionated using strong cation exchange chromatography on a 20AD high-performance liquid chromatography (HPLC) system (Shimadzu, Kyoto, Japan) and a polysulfoethyl column (Nest Group, Southborough, MA, USA) with the following dimensions: 2.1 mm×100 mm, 5
Cartridge (Waters, Milford, MA, USA), diluted with loading 2 PO 4 in 5% acetonitrile [ACN], pH 2.8), and loaded onto the column. Buffer A was identical in composition to the loading buffer. Buffer B was the same as Buffer -tion was performed using a linear binary gradient of 0% to Absorbances at 214 and 280 nm were monitored. Thirty strong cation exchange fractions were collected along the gradient, dried, dissolved in Buffer C (5% ACN and 0.1% formic acid [FA]), and analyzed on a Triple TOF 5600 mass spectrometer (Applied Biosystems). Peptides were separated on a Zorbax 300SB-C18 reverse-phase column (Agilent Technologies, Santa Clara, CA, USA) with the following dimensions: 0.1 mm×15 65 min. Survey scans were acquired from m/z 400 to 1800, with m/z 100-2000 using a dynamic exclusion of 30 S for selected ions. iTRAQ-labeled peptides were fragmented under collision-induced dissociation conditions to yield reporter ions at 113.1, 114.1, 115.1, 116.1, 117.1, abundance of the peptides and proteins in the samples. Larger sequence information-rich fragment ions were also produced of the protein from which the peptide originated.
Bioinformatics analysis
Protein Pilot v4.5 (Applied Biosystems) was used to identify and quantify iTRAQ-labeled peptides. This software was also using UniProt. The rat database was used because the hamster database is not available. The precursor and iTRAQ fragment tolerance values were set to 100 ppm and 0.6 Da. The following parameters were used for data analysis: sample type = iTRAQ (peptide-labeled); Cys alkylation = methyl methaneand database = Swissprot Rat (35 672 entries). A decoy database search strategy was used to estimate an the occurrence of false-positive results. At least one peptide with a confidence interval of 95% was included. Data were considered reliable at P<0.05 and error factor <2. The P value from Student's t the change in protein expression level. Fold-change ratios <0.7 (downregulated) or >1.3 (upregulated) were selected as cutoff -were up-or down-regulated by berberine or berberine8998 treatment. A search of the Kyoto Encyclopedia of Genes and pathway.html) identified the signaling pathways of the proteins. MATLAB (MathWorks, Natick, MA, USA) was used for mathematical modeling and analysis of KEGG pathways.
Western blotting of the candidate proteins -cyl sulfate-polyacrylamide gel electrophoresis and transferred a semi-dry transfer system (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% BSA in buffer composed 20 at room temperature for 2 h. Membranes were incubated with mouse monoclonal antibodies against LDLR (1:2000) and ACOX1 (1:200) (both from Abcam, Cambridge, UK) at 4 °C overnight. Membranes were washed and incubated with anti-mouse IgG (1:2000; Bio-Rad) at room temperature for 2 h. Protein bands were detected using a Clarity Enhanced Chemiluminescence Western Blot Substrate kit (Bio-Rad). Densitometry was performed using Quantity One software (Bio-Rad). The ratio of gray values of target proteins represented the relative expression levels for each group. Each experiment was repeated three times.
Measurement of NEFA levels
Serum samples from 60 hamsters were divided into berberine-, berberine8998-treated and untreated (control) groups (n=20 each). NEFA levels were determined using an assay that measures the conversion of fatty acids to acyl-CoA in the presence of acyl-CoA synthetase. Acyl-CoA is oxidized following the addition of acyl-CoA oxidase, which generates hydrogen peroxide and causes oxidative condensation of 3-methyl-N-ethyl-N presence of a peroxidase to yield a product with an absorbance at 550 nm on an Automatic Biochemical Analyzer. The NEFA-HA Test Kit (Wako, Japan) was used for this measurement. Measurement of DiI-LDL uptake by HepG2 cell LDLRs HepG2 cells were maintained in Dulbecco's modified Eagles' medium (DMEM) (HyClone) containing 10% (v v) fetal bovine -sphere of 95% O 2 and 5% CO 2 at 37 °C at a density of 10 6 cells per mL. HepG2 cells were incubated with DiI-LDL (Biotium, Hayward, CA, USA) and the following test compounds: pravas-LDL uptake was determined as follows. The culture medium was removed, and plates were washed three times with 0.4% --lar Devices, Silicon Valley, CA, USA). The hepatic hydrogen peroxide level was measured using a hydrogen peroxide testing kit (Beyotime Biotech, Haimen, China). The hepatic lipoperoxide level was tested using a malondialdehyde (MDA) testing kit (Nanjing Jiancheng Biotech, Nanjing, China).
Pharmacokinetic study of berberine8998
Male Sprague-Dawley (SD) rats (clean class, 180-200 g, n=10) were provided by the Animal Center of Shanghai Institute of Materia Medica and randomly divided into two groups. After twelve hours of food deprivation, berberine and berberine8998 groups intragastrically (ig). The washout interval between the Rats received the other compound during the second treatment period. The sample collection protocol was identical in the two treatment periods. Blood samples (0.5 mL) were collected pre-dose and at 0.5, 1, 2, 3, 5, 6, 7, 8, 12, 24 , and 48 h after dosing in each treatment period. The collected blood samples were centrifuged at 3000×g for 15 min at 4 °C within 30 min of collection. Serum samples were fractionated by chromatography on a 20AD high-performance liquid chromatography (HPLC) system (Shimadzu, Kyoto, Japan) using a reversephase column (CAPCELL PAK C18). Chromatographic data were processed using Phoenix ® WinNonlin ® 6.3 to calculate the pharmacokinetic parameters.
Similar procedures were used in Syrian hamsters. Syrian hamsters (clean class, 90-120 g, n=6) were provided by the Animal Center of Shanghai Institute of Materia Medica and randomly divided into two groups. Hamsters were food free base) were administered intragastrically (ig). Blood samples (0.5 mL) were collected pre-dose and at 0.5, 1.5, 3, 6, 8 h after dosing in each treatment period.
Results
Berberine8998 ameliorates high-fat diet-induced hypercholesterolemia in hamsters
We initially evaluated the effects of berberine8998 on lipid levels in vivo. Six-week-old male hamsters on a high-fat diet received 50 mg·kg -1 ·d -1 berberine, 50 mg·kg -1 ·d -1 berberine8998 or CMC-Na for 3 weeks. Hamsters on chow diet were administered CMC-Na as the normal diet control group. Serum lipid levels, including total cholesterol, low-density lipoprotein cholesterol, triglyceride and high-density lipoprotein cholesterol, were analyzed weekly.
Hypercholesterolemia developed slowly in the normal diet group (Figure 2A-2C) , and serum lipid levels in the highfat diet (HFD) group increased significantly (Figure 2A-2C) . Notably, berberine8998 treatment significantly reduced total cholesterol ( Figure 2A ) and LDL-c ( Figure 2B ) levels at week 2 and week 3 compared with the HFD group (P<0.05). In contrast, berberine did not alter the LDL-c levels after three weeks of treatment ( Figure 2B ). Mean LDL-c levels at week 2 and respectively, for the berberine8998 group ( Figure 2B ).
Given that triglyceride (TG) is an important component of lipids, the serum TG levels in hamsters were evaluated. The results showed that berberine8998 treatment ameliorated the HFD-induced elevated TG serum levels reducing it by 64% by week 3 in the berberine (P<0.05) and berberine8998 groups (P -ent between the treatment, control and normal diet groups, as shown in Figure 2D .
GO analysis indicates similar cellular protein locations in the berberine and berberine8998 treatment groups Hamster liver samples from the berberine, berberine8998 and high-fat diet model groups were analyzed using iTRAQ shotgun proteomics. High-abundance proteins were depleted prior to analysis. A total of 2049 and 2020 proteins were idenwith a false discovery rate lower than 1%. Combined results of the two replicates identified 2444 proteins, of which 2073
To elucidate the location and function of these proteins, gene ontology analysis and KEGG analysis were conducted. GO analysis revealed that proteins were located in similar cellular components in the high-fat diet group, berberine treatment components were cell part, organelle part, organelle, macromolecular complex and membrane-enclosed lumen. The top five molecular functions included binding, catalytic activity, structural molecule activity, transporter activity and enzyme regulator activity ( Figure 3A) .
KEGG analysis indicates similar metabolic pathways affected in berberine and berberine8998 treatment groups A total of 442 differentially expressed proteins were screened in both runs in the berberine8998 group, and a total of 268 differentially expressed proteins were screened in both runs in liver protein expression levels between sample groups, fold-changes in median ratios <0.7 (downregulated) or >1.3 (upregulated) were selected as cutoff values, and ratios were assessed using Student's t test. The median values of the ratios between the two groups were also calculated. A total of group; 16 proteins were upregulated, and 32 proteins were downregulated. A total of 53 proteins exhibited significant changes in the berberine group; 23 proteins were upregulated, and 30 proteins were downregulated. The top ten most sigberberine treatment are summarized in Table 1 and Table 2. KEGG metabolic pathways were analyzed to determine the major pathways involved in berberine and berberine8998 treatment and statistical analysis determined the pathways represented in the berberine and berberine8998 treatment groups. As shown in Figure 3B , the major KEGG pathways were fatty acid metabolism, ribosome, pyruvate metabolism, propanoate metabolic pathway was fatty acid metabolism. These results suggest that berberine8998 and berberine lowered serum lipid levels via similar metabolic pathways.
Fatty acid metabolism is the major pathway affected by berberine8998
Although the major metabolic pathways were similar in berberine and berberine 8998 treatment groups, the differences in the magnitude of the target proteins were examined. Bioinformatics analysis revealed that fatty acid metabolism was the of these agents. Therefore, two of the differentially expressed proteins, ACOX1 and ACSL1 were selected for validation by Western blotting. ACOX1 and ACSL1 expression in the liver was downregulated in the berberine and berberine8998 treatment groups compared to the control group ( Figure 4A ). The protein expression of ACOX1 and ACSL1 was significantly decreased by berberine8998 treatment by approximately 2-to 3-fold while the berberine treatment decreased ACOX1 and ACSL1 expression by approximately 1-to 2-fold. Therefore, the magnitude of ACOX1 and ACSL1 protein expression varied between the berberine and berberine8998 treatment groups. -lism. Serum non-esterified fatty acid levels were analyzed because of the reduced TG levels in vivo ( Figure 2C ). Serum NEFA levels exhibited similar changes (4.07 vs P<0.05; Figure 4B ) compared to the high-fat diet group. These results suggest that berberine8998 reversed the HFD-induced increase in serum TG and NEFA levels.
To further elucidate the mechanisms associated with decreased serum LDL levels by berberine8998, a Dil-LDL uptake experiment was performed in HepG2 cells. Berberin HepG2 cells compared with berberine (2.26 vs 1.22, P<0.01) ( Figure 4C ). The LDLR mediates LDL uptake in HepG2 cells. Therefore, the LDLR expression was evaluated in HepG2 cells by Western blotting. As shown in Figure 4D , LDLR was upregulated dose-dependently by treatment with both berberine and berberine8998, and berberine8998 induced a greater effect. the uptake of LDL via increasing the expression of LDLR.
To elucidate the mechanisms involved in the effect of ACOX1 on fatty acid metabolism, hepatic malondialdehyde (MDA) and peroxide levels were analyzed. Additionally, and UCP-1 expression. The results showed that hepatic malondialdehyde (MDA) and peroxide levels were inhibited, expression increased following treatment ( Figure 4E-4G ).
The pharmacokinetics of berberine8998 and berberine were further evaluated in SD rats. The mean serum concentration vs -cokinetic parameters of berberine and berberine8998 are summarized in Table 3 . The maximum concentrations of berberine and berberine8998 in the serum (C max -ine8998 in serum (t ) were 29.18 h and 10.97 h, respectively. The areas under the curve (AUC These results suggest that the bioavailability of berberine Similar results were also observed in hamsters ( Figure 5B and Table 4) , with the bioavailability enhance by 3.6 times in hamsters. Beta-oxidation of fatty acids. The highest activity concerns the C6 to C10 chain length substrate. Removes terminal alpha-N-acetylgalactosamine residues from glycolipids and glycopeptides. One of the major pre-mRNA-binding proteins.
Discussion
Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs.
Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100).
The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by acInvolved in the recruitment, assembly and/or regulation of a variety of signaling molecules. Catalyzes the oxidation of uric acid to 5-hydroxyisourate, which is further processed to form (S)-allantoin. Liver regeneration. Ribosomal small subunit assembly. Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses oleate, arachidonate, eicosapentaenoate and docosahexaenoate as substrates. of high-fat hamster liver tissues samples with or without berberine8998 treatment. This study was the first time that the 5600) to investigate the mechanisms of action of berberine and berberine8998. Two differentially expressed proteins (ACOX1 selectively validated further using Western blotting and biochemical analyses. The differences in protein expression may be the result of the improvement in the bioavailability of berberine8998. The effects of berberine8998 on serum lipids were detertotal TC and TG levels following berberine8998 treatment. Berberine reduced TC and TG but with reduced potency. To elucidate the possible mechanisms involved in this improvement, the function, interplay and changes in the abundance of proteins in response to internal and external cues were investigated [15] . The iTRAQ method combined with two-dimensional Catalyzes the removal of unsubstituted N-terminal amino acids from various peptides. Involved in membrane trafficking between the Golgi complex and endosomes. Binds to the signal sequence of presecretory protein when they emerge from the ribosomes and transfers them to TRAM (translocating chain-associating membrane protein). Involved in the recruitment, assembly and/or regulation of a variety of signaling molecules. 2acetyl-CoA = CoA + acetoacetyl-CoA. F-actin cross-linking protein which is thought to anchor actin to a variety of intracellular structures. Serine/threonine kinase which acts as a negative regulator of Ras-related Rap2-mediated signal transduction to control neuCatalyzes the reduction of a wide variety of carbonyl compounds includingquinones, prostaglandins, menadione, plus various xenobiotics. Required for protein transport from the endoplasmic reticulum to the Golgi complex. Introduces a double bond at position 2 in saturated acyl-CoAs of short chain length. Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses oleate, arachidonate, eicosapentaenoate and docosahexaenoate as substrates. Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs. Isoform 1 shows highest activity against medium-chain fatty acyl-CoAs and activity decreases with increasing chain length. Isoform 2 is active against a much broader range of substrates and shows activity towards very long-chain acyl-CoAs. Isoform 1 shows optimum activity with a chain length of 10 carbons while isoform 2 exhibits optimum activity with 14 carbons.
liver tissues of mice maintained on a high-fat diet treated with either berberine or berberine8998.
Previous studies investigated the proteomic effects of berberine on multi-target antimicrobial [13] and breast cancer cells [17] hamsters have not been investigated previously. This technique is one of the most powerful methodologies in quantitative proteomics [18] 16 proteins were upregulated, and 32 proteins were downregin the berberine group: 23 proteins were upregulated, and 30 proteins were downregulated.
GO analysis showed that the differentially expressed proteins in the treatment and control groups had similar cellular locations. KEGG pathway enrichment suggested that fatty acid metabolism was specifically activated by the treatment. Hepatic ACOX1 expression was significantly lower in the berberine8998 altered the levels of ACOX1 and other related proteins. These results suggest that berberine8998 reduces serum NEFA levels via modulation of ACOX1 expression. iTRAQ proteomics revealed that the effect of berberine8998 on TG was mediated by NEFA and hepatic ACOX1 expression.
NEFA was downregulated by berberine8998. This ACOX1-regulated mechanism suppressed TG and NEFA levels in vivo, which is a newly defined lipid-lowering mechanism of berberine8998. Further mechanistic studies revealed that berberine8998 enhanced hepatic LDL uptake by increasing LDLR expression. Consistent with the lipid lowering effect, berberine8998 exhibited increased bioavailability in SD rats compared with berberine, and the mechanisms involved require further investigation.
Reductions in total cholesterol and LDL were observed in the berberine and berberine8998 groups. The mechanisms of cholesterol lowering by berberine8998 were similar to those of berberine. Increased uptake of LDL in HepG2 cells and the upregulation of LDLR expression were observed in both that berberine and, to a greater extent, berberine8998 stimulated the uptake of LDL in HepG2 cells, which is similar to the cholesterol-lowering agent pravastatin. The intensity (a.u.) of Dil-LDL in HepG2 cells was measured to compare the lipid uptake amounts of a positive control group (Pravastatin) to the berberine and berberine8998 groups. Western blot analyses showed that the upregulation of LDLR expression was greater in cells treated with berberine8998 than in those treated with berberine, which indicates that berberine8998 has superior lipid-lowering effects to the parent molecule in vitro. As shown in Figure 4E -4G, hepatic malondialdehyde (MDA) and peroxide levels were inhibited, though this difference did and UCP-1 expression were increased by treatment ( Figure  4E-4G ). ACOX1 inhibition was reported to improve hepatic lipid and reactive oxygen species metabolism [13] , which was similarly observed in the present study. Therefore, inhibition of ACOX1 appears involved in the lipid-lowering effects of berberine8998. The berberine derivatization into berberine8998 greatly improved drug absorption. This high availability of berber--cacy. The mechanisms of the absorption-improving of berberine8998 will be examined in future studies. and total cholesterol levels via upregulation of hepatic LDLR expression. The reduction in TG levels in berberine8998-treated hamsters was associated with lower NEFA levels. iTRAQ proteomic studies revealed that ACOX1 was significantly inhibited in the berberine8998 treatment group. The effect of berberine8998 on TG was mediated by NEFA and hepatic ACOX1 expression. This ACOX1-regulated mechanism suppressed the TG and NEFA levels in vivo, which is a -berine8998. The improved bioavailability of berberine8998 is -ies.
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